Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities
Abstract Significant advances in the development of new cancer therapies have given rise to multiple novel therapeutic options in chemotherapy, radiotherapy, immunotherapy, and targeted therapies. Although the development of resistance is often reported along with temporary disease remission, there...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202403936 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582778656391168 |
|---|---|
| author | Mohammad Burhan Uddin Zhishan Wang Chengfeng Yang |
| author_facet | Mohammad Burhan Uddin Zhishan Wang Chengfeng Yang |
| author_sort | Mohammad Burhan Uddin |
| collection | DOAJ |
| description | Abstract Significant advances in the development of new cancer therapies have given rise to multiple novel therapeutic options in chemotherapy, radiotherapy, immunotherapy, and targeted therapies. Although the development of resistance is often reported along with temporary disease remission, there is often tumor recurrence of an even more aggressive nature. Resistance to currently available anticancer drugs results in poor overall and disease‐free survival rates for cancer patients. There are multiple mechanisms through which tumor cells develop resistance to therapeutic agents. To date, efforts to overcome resistance have only achieved limited success. Epitranscriptomics, especially related to m6A RNA modification dysregulation in cancer, is an emerging mechanism for cancer therapy resistance. Here, recent studies regarding the contributions of m6A modification and its regulatory proteins to the development of resistance to different cancer therapies are comprehensively reviewed. The promise and potential limitations of targeting these entities to overcome resistance to various anticancer therapies are also discussed. |
| format | Article |
| id | doaj-art-c30df69b15544a599fbe01eb40c94bf7 |
| institution | Kabale University |
| issn | 2198-3844 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj-art-c30df69b15544a599fbe01eb40c94bf72025-01-29T09:50:18ZengWileyAdvanced Science2198-38442025-01-01124n/an/a10.1002/advs.202403936Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized OpportunitiesMohammad Burhan Uddin0Zhishan Wang1Chengfeng Yang2Department of Pharmaceutical Sciences North South University Bashundhara Dhaka 1229 BangladeshStony Brook Cancer Center Stony Brook University Stony Brook NY 11794 USAStony Brook Cancer Center Stony Brook University Stony Brook NY 11794 USAAbstract Significant advances in the development of new cancer therapies have given rise to multiple novel therapeutic options in chemotherapy, radiotherapy, immunotherapy, and targeted therapies. Although the development of resistance is often reported along with temporary disease remission, there is often tumor recurrence of an even more aggressive nature. Resistance to currently available anticancer drugs results in poor overall and disease‐free survival rates for cancer patients. There are multiple mechanisms through which tumor cells develop resistance to therapeutic agents. To date, efforts to overcome resistance have only achieved limited success. Epitranscriptomics, especially related to m6A RNA modification dysregulation in cancer, is an emerging mechanism for cancer therapy resistance. Here, recent studies regarding the contributions of m6A modification and its regulatory proteins to the development of resistance to different cancer therapies are comprehensively reviewed. The promise and potential limitations of targeting these entities to overcome resistance to various anticancer therapies are also discussed.https://doi.org/10.1002/advs.202403936cancer stem cellcancer therapy resistanceepitranscriptomicsm6A modificationm6A regulator inhibitors |
| spellingShingle | Mohammad Burhan Uddin Zhishan Wang Chengfeng Yang Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities Advanced Science cancer stem cell cancer therapy resistance epitranscriptomics m6A modification m6A regulator inhibitors |
| title | Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities |
| title_full | Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities |
| title_fullStr | Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities |
| title_full_unstemmed | Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities |
| title_short | Epitranscriptomic RNA m6A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities |
| title_sort | epitranscriptomic rna m6a modification in cancer therapy resistance challenges and unrealized opportunities |
| topic | cancer stem cell cancer therapy resistance epitranscriptomics m6A modification m6A regulator inhibitors |
| url | https://doi.org/10.1002/advs.202403936 |
| work_keys_str_mv | AT mohammadburhanuddin epitranscriptomicrnam6amodificationincancertherapyresistancechallengesandunrealizedopportunities AT zhishanwang epitranscriptomicrnam6amodificationincancertherapyresistancechallengesandunrealizedopportunities AT chengfengyang epitranscriptomicrnam6amodificationincancertherapyresistancechallengesandunrealizedopportunities |